MHRA warns of dangers of fake weight loss pens after Yellow Card reports The medicines regulator said Ozempic and Saxenda pens have been confirmed as being falsified with insulin in five of the reports.…
Tirzepatide approved for weight loss treatment by regulator The Medicines and Healthcare products Regulatory Agency has said tirzepatide will be available to patients with obesity, or who are overweight, with weight-related health problems.…
Medicines regulator approves anastrozole for prevention of breast cancer in post-menopausal women NHS England says around 289,000 women at moderate or high risk of breast cancer could benefit from anastrozole.…
MHRA seizes £5m of illegally-traded medicines in 15th year of medicines crime initiative Interpol says the haul from this year's Operation Pangea posed a “significant threat to consumer safety”.…
Safety measures introduced for isotretinoin prescribing in patients aged under 18 years Recommendations to improve the safety of prescribing the acne drug isotretinoin have been made by the Commission on Human Medicines.…
UK regulator seizes 369 potentially fake weight loss pens following reports of hospitalisations The Medicines and Healthcare products Regulatory Agency said the public should consult a healthcare professional qualified to provide semaglutide and liraglutide via prescription.…
UK regulator to consider EMA recommendation to avoid topiramate in pregnancy Exclusive: The UK medicines regulator said it would carefully consider recommendations made by the European Medicines Agency, which were published following a review of data showing an increased risk of developmental disorders among children exposed to topiramate before birth.…
RPS says codeine linctus should be made a prescription-only medicine, in response to MHRA consultation The Royal Pharmaceutical Society says reclassification will make it easier to monitor codeine linctus use, because it will be recorded in GP systems.…
MHRA issues drug safety warning on hyoscine bromide patches The regulator told The Pharmaceutical Journal that there had been seven yellow card reports of anticholinergic syndrome as a side effect of hyoscine hydrobromide patches.…
Would UK approval of lecanemab be a game changer for people with Alzheimer’s disease? Experts are divided over whether lecanemab is a cost-effective intervention for Alzheimer’s disease, raising concerns that the NHS is not ready for it.…
